gemcitabine + cisplatine

DRUG2 trials

Sponsors

Intergroupe Francophone de Cancerologie Thoracique, Fundación de investigación HM

Conditions

MibcMuscle Invasive Bladder CancerNon-small Cell Lung Cancer Stage I and IIPeri-operative Chemotherapy

Phase 2

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Not yet recruitingNCT06623162

Fundación de investigación HMMibc, Muscle Invasive Bladder Cancer

Start: 2024-12-31End: 2027-12-31Target: 70Updated: 2024-10-04

Phase 3

Stage I/II NSCLC Perioperative Chemotherapy

CompletedNCT00198354

Intergroupe Francophone de Cancerologie ThoraciqueNon-small Cell Lung Cancer Stage I and II, Peri-operative Chemotherapy

Start: 2001-05-31End: 2010-12-31Updated: 2016-03-10

Related Papers

Selective bladder-sparing trial with sasanlimab as maintenance treatment based on clinical response to neoadjuvant treatment in molecularly categorized muscle invasive bladder cancer patients: SASAN-SPARING trial.

Journal of Clinical Oncology2026-05-28

Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.

Journal of Clinical Oncology2025-05-28